Gut Microbiota Association With ESBL-E Colonisation and Subsequent ESBL-E Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-15

Study Completion Date

2020-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antimicrobial resistance is a major threat worldwide and extended-spectrum beta-lactamase producing Enterobacteriales (ESBL-E) are a leading cause because of their wide dissemination. Gut microbiota seems to be correlated with multi-drug resistant organism carriage. This study thus aims to analyse the correlation between gut microbiota, ESBL-E fecal carriage and subsequent infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?

NCT04699981

Enterobacteria Infections

UNKNOWN NA

Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae

NCT04903886

Ventilator Associated Pneumonia Bacteremia Abdominal Infection +1 more

UNKNOWN

Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria

NCT03338738

Enterobacterial Infection

COMPLETED NA

Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments

NCT01703299

Carbapenem-induced Resistance

COMPLETED

Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit

NCT04528043

Critically Ill Enterobacteriaceae Infections Antibiotic Resistant Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The rising antimicrobial resistance has led to more than 33,000 deaths in Europe in 2015. Among them, extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are the most frequent in Europe and have disseminated both in the community and in healthcare settings. Some studies have suggested that microbiota could be different between multi-drug resistant organisms, with different relative abundances of some bacteria. One study focused on ESBL-E fecal carriers, but in the community, with Bacteroides uniformis being more abundant in ESBL-E non-carriers than carriers. As identification of species discriminating between ESBL-E fecal carriers and non-carriers could pave the way for the design of ESBL-E carriage eliminating probiotics, we aim to analyse the correlation between gut microbiota and ESBL-E fecal carriage.

Moreover, mechanisms in the link between ESBL-E fecal carriage and subsequent ESBL-E infection remain, so far, poorly understood and this study aims to provide a first insight in the involvement of gut microbiota in the link between colonization and infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extended Spectrum Beta-Lactamase Producing Bacteria Infection Microbial Colonization Critical Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESBL-E fecal carriers

Patients with a positive ESBL-E fecal carriage according to routine screening

ESBL-E fecal carriage screening according to routine care

Intervention Type DIAGNOSTIC_TEST

ESBL-E fecal carriage screening according to routine care

non ESBL-E fecal carriers

Patients without positive ESBL-E fecal carriage according to routine screening

ESBL-E fecal carriage screening according to routine care

Intervention Type DIAGNOSTIC_TEST

ESBL-E fecal carriage screening according to routine care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ESBL-E fecal carriage screening according to routine care

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient above 18 year-old admitted to intensive care unit
* ESBL-E fecal carriage according to current screening recommendations for ESBL-E carriage group
* Feces quantity on rectal swab adequate for routine screening and microbiota analysis